Evolus

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Evolus reports robust Q4 earnings, eyes international expansion and profitability

Evolus' Q4 2022 performance exceeded expectations, driven by strong revenue growth and customer acquisition.
The company's strategic focus on market share gains, international expansion, and profitability sets a positive trajectory.
Challenges from new competition and market dynamics require strategic responses to maintain leadership.
Opportunities in international expansion, corporate development, and market growth position Evolus for future success.

Evolus secures strategic partnership for growth in dermal filler market

Evolus' strong Q1 performance and strategic partnership with Symatese position the company for significant growth in the dermal filler market.
While facing challenges in safety comparisons and patient demographics, Evolus has opportunities to leverage its unique manufacturing process and upcoming data releases for market advantage.
Overall, Evolus is well-funded, poised for profitability, and focused on differentiating its product line for long-term success.

Evolus (EOLS) exceeds Q2 sales targets, eyes international expansion

Evolus (EOLS) delivered a strong performance in Q2, with accelerated sales growth, efficient cost management, and a focus on profitability, positioning the company for future success.
While facing challenges in market penetration and profitability, Evolus's strategic strengths in customer acquisition, innovation, and financial discipline provide a solid foundation for growth.
With opportunities for revenue expansion, international market growth, and disruptive product launches, Evolus is poised to capitalize on its strengths and address key challenges to drive long-term value for investors.

Evolus (EOLS) achieves record revenue and profitability, eyes global expansion

Evolus (EOLS) delivered a stellar performance in Q3 2023, with record revenue, strong financials, and promising R&D outcomes, positioning the company for continued growth and profitability.
The company's strategic strengths lie in market expansion, brand loyalty, and a clear long-term vision, supported by confidence in achieving ambitious revenue targets and product innovation.
While challenges in market competition and resource optimization persist, Evolus has opportunities in market segments, international expansion, and industry visibility to drive future growth.

Evolus surpasses revenue targets, eyes $700 million goal by 2028

Evolus delivered strong financial performance in Q4 2023, exceeding revenue expectations and achieving profitability. With a strategic focus on market expansion, product differentiation, and customer engagement, the company aims to reach a revenue target of $700 million by 2028.

Evolus reports robust Q1 growth, eyes $700M revenue target by 2028

Evolus demonstrated strong financial performance and market expansion in Q1 2024, with a focus on operational efficiency and customer engagement. The company's strategic goals include achieving profitability by year-end and targeting substantial revenue growth by 2028.
While facing challenges in market dynamics and profitability targets, Evolus remains optimistic about its competitive position and growth prospects. Opportunities lie in leveraging loyalty programs, expanding internationally, and launching new product lines to drive future success.

Evolus reports profitable Q2, eyes global expansion and new products

Evolus demonstrated strong performance in Q2 2024, achieving profitability and revenue growth.
The company's focus on innovation, international expansion, and financial management positions it for future success.
Challenges lie in maintaining growth momentum, executing expansion plans, and managing costs effectively.
Opportunities include capitalizing on market demand, global expansion, product innovation, and financial optimization.

Evolus reports strong Q3 growth, eyes $700M revenue target

Evolus showcased robust growth and strategic initiatives in Q3 2024, aiming for significant revenue targets by 2028. While facing revenue challenges and market competition, the company's strengths in product innovation and market expansion offer opportunities for sustained growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that it will report its fourth quarter and year end 2021 financial results and provide a business update on Thursday, March 3, 2022.

Evolus to Report Fourth Quarter and Year End 2021 Results and Provide Business Update

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces the acceptance of its submission to the Australian Therapeutics Good Administration for regulatory approval of Nuceiva®

Evolus Receives Acceptance of Submission in Australia, a Pivotal Step in Approval Process for Nuceiva®

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that members of its management team will be participating in the Virtual 11th Annual SVB Leerink Global Healthcare Conference.

Evolus to Participate in the Virtual 11th Annual SVB Leerink Global Healthcare Conference

Evolus Inc (NASDAQ: EOLS) has posted interim Q4 sales of approximately $34.7 million (better than the consensus of $30.87 million), up 68% Y/Y, driven by higher volumes and a higher average selling price. Total sales for FY21 are expected to be approximately $99.7 million, +76% Y/Y.

Evolus Expects Q4 FY21 Sales Better Than Anticipated, Issues FY22 Guidance

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces its preliminary, unaudited net revenue and cash position as of and for the fourth quarter and full-year ended December 31, 2021.

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Net Revenue and Provides 2022 Guidance

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that it has further strengthened and diversified its Board of Directors with the appointment of Brady Stewart.

Evolus Expands Board of Directors With Appointment of Digital and Beauty Innovator Brady Stewart

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that its common stock has been selected for inclusion in the Nasdaq Biotechnology Index effective today.

Evolus Joins Nasdaq Biotechnology Index

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus, a performance beauty company, has entered into a $125 million term loan financing facility with funds managed by Pharmakon Advisors, L.P.

Evolus Enters Into $125 Million Credit Facility with Pharmakon Advisors

Evolus, Inc. (EOLS) CEO David Moatazedi on Q3 2021 Results - Earnings Call Transcript

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of 18.75% and -1.08%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Evolus, Inc. (EOLS) Reports Q3 Loss, Lags Revenue Estimates

NEWPORT BEACH, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results for the third quarter ended September 30, 2021 and provided a business update.

Evolus Reports Third Quarter 2021 Results and Provides Business Update

NEWPORT BEACH, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it has initiated a clinical program to study an “extra strength” dose for extended duration of Jeuveau® (prabotulinumtoxinA-xvfs), its flagship neurotoxin product and first and only neurotoxin dedicated exclusively to aesthetics.

Evolus Initiates Phase II Program with “Extra Strength” Dose for Extended Duration

NEWPORT BEACH, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that Jessica Novak, SPHR has joined the company as Senior Vice President, Human Resources where she will oversee global efforts to expand, retain and develop an entrepreneurial team bringing innovative products and marketing solutions to the aesthetics industry.

Evolus Announces Appointment of Jessica Novak as Senior Vice President, Human Resources

Evolus, Inc. (EOLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Evolus, Inc. (EOLS) Expected to Beat Earnings Estimates: Should You Buy?

NEWPORT BEACH, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its third quarter 2021 financial results and provide a business update on Tuesday, November 2, 2021, prior to the open of the U.S. financial markets.

Evolus to Report Third Quarter 2021 Results and Provide Business Update

NEWPORT BEACH, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in two investment conferences in September.

Evolus Announces Participation in September Investment Conferences

Evolus, Inc. (EOLS) CEO David Moatazedi on Q2 2021 Results - Earnings Call Transcript

Record Quarter: Net Revenue Grew 235% Year-over-Year to $26.1 Million

Evolus Reports Second Quarter 2021 Results and Provides Business Update

This small-cap stock is going after a billion-dollar market.

Can Evolus Disrupt the Botox Market?

NEWPORT BEACH, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that David K. Erickson has joined the company as Vice President, Investor Relations where he will be responsible for developing, implementing and managing a comprehensive and strategic investor relations program.

Evolus Announces Appointment of David K. Erickson as Vice President, Investor Relations

NEWPORT BEACH, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced a peer reviewed journal article was published in Dermatologic Surgery (April 2021) highlighting the efficacy and safety of prabotulinumtoxinA (Jeuveau®) for the treatment of moderate to severe glabellar lines, also known as frown lines between the eyes, in adult patients with Skin of Color (SOC).

Peer Reviewed Article Highlights Efficacy and Safety of Jeuveau® in Patients with Skin of Color

NEWPORT BEACH, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the appointment of Dan Stewart as Vice President and General Manager of the company's International business.

Evolus Appoints Dan Stewart as Vice President and General Manager, International

Evolus, Inc. (EOLS) CEO David Moatazedi on Q1 2021 Results - Earnings Call Transcript

Q1 2021 Net Revenues of $12.2 million, Despite Half-Quarter ITC Impact

Evolus Reports First Quarter 2021 Results and Provides Business Update

Evolus Inc (NASDAQ: EOLS) has announced two newly published peer review studies in Aesthetic Surgery Journal that provide supportive evidence of the safety and efficacy of repeat doses of prabotulinumtoxinA (Jeuveau) to decrease the appearance of glabellar lines (also known as frown lines between the eyes). The two Phase 2 studies demonstrate that prolonged use of Jeuveau is safe and effective with repeat treatments.

News for Evolus Stock (EOLS)